IL1B and gout: Combined with strategies to reduce risk factors and interventions such as fenofibrate (57), febuxostat (58), and the IL-1β-targeting monoclonal antibody canakinumab (59), this approach could aid in developing preventive measures to reduce the incidence of gout.